In one of two companion diagnostics deals it signed on the same day, Roche Diagnostics Corp.’s Ventana Medical Systems Inc. (tissue analysis) will create a test for oncology drug developer AEterna Zentaris Inc.’s AEZS108 for the immunohistochemical determination of luteinizing hormone-release hormone (LHRH) receptor expression. (Jan.)
AEterna will use this diagnostic to select ideal patients for AEZS108, a Phase II formulation of doxorubicin which is conjugated to a synthetic peptide (zoptarelin) that directs chemotherapy specifically to...